Literature DB >> 30129654

PCNA-associated factor P15PAF , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.

Chengjuan Jin1,2, Zhaojian Liu3, Yingwei Li1, Hualei Bu1, Yu Wang1, Ying Xu1, Chunping Qiu1, Shi Yan1, Cunzhong Yuan1, Rongrong Li1, Nannan Diao4, Zhiwei Zhang1, Xiangxiang Wang1, Lidong Liu1, Beihua Kong1.   

Abstract

Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer. In this study, we demonstrated that P15PAF (KIAA0101) was significantly upregulated in high-grade serous ovarian cancer (HGSOC) and that high KIAA0101 expression was associated with poor prognosis. FOXM1 transcriptionally activated KIAA0101 to drive proliferation and metastasis of ovarian cancer cells. KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance. Thus, KIAA0101 was closely related to the FOXM1 and PI3K/AKT/mTOR signaling pathways. Collectively, these findings provide insights into the mechanisms of poor prognosis of ovarian cancer and have implications for the development of both predictive and therapeutic biomarkers for the treatment of ovarian cancer.
© 2018 UICC.

Entities:  

Keywords:  FOXM1; HGSOC; P15PAF; PI3K/AKT/mTOR

Mesh:

Substances:

Year:  2018        PMID: 30129654     DOI: 10.1002/ijc.31800

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.

Authors:  Mei Li; Xu-Dong Mu; Juan-Rong Song; Peng-Tao Zhai; Yuan Cheng; Yao Le; Zhu-Bin Li
Journal:  Cell Cycle       Date:  2021-05-10       Impact factor: 4.534

2.  Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.

Authors:  Hualei Bu; Yingwei Li; Chengjuan Jin; Hongfeng Yu; Xiangxiang Wang; Jingying Chen; Yu Wang; Yana Ma; Youzhong Zhang; Beihua Kong
Journal:  Int J Oncol       Date:  2020-01-10       Impact factor: 5.650

3.  Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples.

Authors:  Audra N Iness; Lisa Rubinsak; Steven J Meas; Jessica Chaoul; Sadia Sayeed; Raghavendra Pillappa; Sarah M Temkin; Mikhail G Dozmorov; Larisa Litovchick
Journal:  Front Oncol       Date:  2021-03-04       Impact factor: 6.244

4.  Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma.

Authors:  Junhui Liu; Lun Gao; Jianmin Liao; Ji'an Yang; Fan'en Yuan; Qianxue Chen
Journal:  Ann Transl Med       Date:  2021-02

5.  Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis.

Authors:  Di Wu; Yun Pan; Xueyong Zheng
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

6.  Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors.

Authors:  Xiaowei Liu; Cheng Cheng; Yuanxia Cai; Yaoyao Gu; Yangkun Wu; Kai Chen; Zhixiang Wu
Journal:  Int J Oncol       Date:  2022-04-15       Impact factor: 5.884

Review 7.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 8.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

Review 9.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

10.  Increased KIAA0101 gene expression associated with poor prognosis in breast cancer.

Authors:  Jiuyang Liu; Yukun He; Chengxin Li; Rui Zhou; Qianqian Yuan; Jinxuan Hou; Gaosong Wu
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.